Rational Analysis of the Use of Antidiabetic Drugs in Pregnant Women Patients at Z Hospital in 2023

Abstract

This study aims to evaluate the level of rationality of the use of antidiabetic drugs in patients with Gestational Diabetes Mellitus (DMG) at Z Hospital in 2023. This study was non-experimental descriptive with a cross-sectional approach using medical record data of 82 patients who met the inclusion and exclusion criteria. The data was analyzed based on four parameters of rationality for drug use, namely accuracy of diagnosis, accuracy of indications, accuracy of medication, and accuracy of dose. The results showed that the level of rationality for the use of antidiabetic drugs was included in the very good category, with an accuracy of diagnosis and indications of 100%, a drug accuracy of 97.5%, and a dose accuracy of 92.68%. The most widely used type of drug is insulin aspart (rapid acting) either alone or in combination with insulin detemir or glargine (long acting). These results show that the use of antidiabetic drugs in DMG patients at Z Hospital is in accordance with WHO therapy guidelines and rational clinical pharmaceutical practices. This research is expected to be the basis for further research on the relationship between the rationality of drug use and patient clinical outcomes and support the development of clinical pharmacy policies that are more effective and safe for pregnant women.